Evidence map›Paper›PMID 24686988›Full record

ReviewBone marrow transplantation2014

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

M Mohty, K Hübel, N Kröger, M Aljurf, J Apperley, G W Basak, A Bazarbachi, K Douglas, I Gabriel, L Garderet and 18 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Pre-emptive increase in the filgrastim dose based on the CD34Hematology, transfusion and cell therapy · 2024
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

M MohtyDepartment of Haematology, Saint Antoine Hospital, Paris, France.
K HübelUniversity Hospital Cologne, Cologne, Germany.
N KrögerUniversity Hospital Hamburg-Eppendorf, Hamburg, Germany.
M AljurfKing Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabi.
J ApperleyImperial College London, London, UK.
G W BasakThe Medical University of Warsaw, Warsaw, Poland.
A BazarbachiAmerican University of Beirut, Beirut, Lebanon.
K DouglasBeatson West of Scotland Cancer Centre, Glasgow, UK.
I GabrielImperial College London, London, UK.
L GarderetDepartment of Haematology, Saint Antoine Hospital, Paris, France.
C GeraldesUniversity Hospital Coimbra, Coimbra, Portugal.
O JaksicUniversity Hospital Dubrava, Zagreb, Croatia.
M W KattanQuantitative Health Sciences Cleveland Clinic, Cleveland, OH, USA.
Z KoristekDepartment of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
F LanzaCremona Hospital, Cremona, Italy.
R M LemoliUniversity of Genoa, Genoa, Italy.
L MendeleevaNational Research Centre for Haematology, Moscow, Russia.
G MikalaSt Istvan and St Laszlo Hospital, Budapest, Hungary.
N MikhailovaInstitute of Children Haematology and Transplantation n.a. R Gorbacheva, St Petersburg State Pavlov Medical University, St Petersburg, Russia.
A NaglerChaim Sheba Medical Center, Tel Hashomer, Israel.
H C SchoutenMaastricht University Medical Centre, Maastricht, The Netherlands.
D SelleslagDepartment of Haematology, AZ Sint-Jan, Brugge-Oostende, Belgium.
S SuciuEORTC Headquarters, Brussels, Belgium.
A SuredaAddenbrooke's Hospital, Cambridge, UK.
N WorelMedical University Vienna, Vienna, Austria.
P WuchterDepartment of Medicine V, Heidelberg University, Heidelberg, Germany.
C ChabannonInstitut Paoli-Calmettes and Inserm CBT-510, Marseille, France.
R F DuarteCatalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or lymphoma after myeloablative chemotherapy. Twenty-eight experts from the European Group for Blood and Marrow Transplantation developed a position statement on the best approaches to mobilising PBSCs and on possibilities of optimising graft yields in patients who mobilise poorly. Choosing the appropriate mobilisation regimen, based on patients' disease stage and condition, and optimising the apheresis protocol can improve mobilisation outcomes. Several factors may influence mobilisation outcomes, including older age, a more advanced disease stage, the type of prior chemotherapy (e.g., fludarabine or melphalan), prior irradiation or a higher number of prior treatment lines. The most robust predictive factor for poor PBSC collection is the CD34(+) cell count in PB before apheresis. Determination of the CD34(+) cell count in PB before apheresis helps to identify patients at risk of poor PBSC collection and allows pre-emptive intervention to rescue mobilisation in these patients. Such a proactive approach might help to overcome deficiencies in stem cell mobilisation and offers a rationale for the use of novel mobilisation agents.

Indexed as

EuropeHematopoietic Stem Cell MobilizationHumansLymphomaMultiple MyelomaTransplantation, Autologous

Identifiers

PMID24686988

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.